支气管动脉灌注化疗与全身静脉化疗治疗晚期非小细胞肺癌的疗效及安全性的Meta分析

发布时间：2018-07-25 16:46

【摘要】：背景与目的：肺癌是中国目前发病率及死亡率最高的恶性肿瘤之一,本研究旨在探讨脉灌注化疗与静脉全身化疗在中晚期非小细胞肺癌患者治疗中的有效性及安全性。方法：计算机检索PubMed、 Cochranelibrary、中国生物医学文献数据库(CBM)、中国知识资源总库(CNKI)、万方数据在线知识服务平台,收集国内外2000年-2014年间公开发表的有关支气管动脉灌注化疗与全身静脉化疗临床对照试验的中英文文献,按照入选标准严格筛选文献并对文献质量进行评估,对最终入选的文献使用RevMan5.0软件进行Meta分析。结果：纳入分析的文献共计11篇,Meta分析显示支气管灌注化疗组有效率明显高于全身静脉化疗组(RR,1.57; 95%CI,1.37-1.82; P0.001; 12=0%),但两组患者1年生存率无统计学差异(RR,1.10; 95%CI,0.91-1.33;P=0.30;I2=24%)。支气管动脉灌注化疗组血小板降低发生率显著低于全身静脉化疗组(RR,0.64; 95%CI,0.30-1.37; P=0.006; 12=0%),但2组患者白细胞降低发生率无统计学差异(RR,0.77; 95%CI, 0.56-1.04; P=0.09; 12=87%),恶心、呕吐发生率亦无统计学差异(RR, 0.64; 95%CI,0.30-1.37; P=0.25; I2=98%)。结论：支气管动脉化疗对晚期非小细胞肺癌的有效率明显高于全身静脉化疗,且在一定程度上能降低某些化疗不良反应的发生,可作为部分晚期非小细胞肺癌患者首选治疗方式之一。
[Abstract]:Background & objective: lung cancer is one of the malignant tumors with the highest morbidity and mortality in China. The purpose of this study was to investigate the efficacy and safety of pulse infusion chemotherapy and intravenous systemic chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: the online knowledge service platform of PubMed, Cochranelibrary, (CBM), China knowledge Resource General Database (CNKI),) was searched by computer. To collect the Chinese and English literature on clinical controlled trials of bronchial artery infusion chemotherapy and systemic intravenous chemotherapy published at home and abroad from 2000 to 2014, and to screen the literature strictly according to the inclusion criteria and evaluate the quality of the literature. The final selected documents were analyzed by Meta using RevMan5.0 software. Results: a total of 11 meta-analysis papers showed that the effective rate of bronchial infusion chemotherapy group was significantly higher than that of systemic intravenous chemotherapy group (RRN 1.57; 95CII 1.37-1.82; P0.001; 120.0%), but there was no significant difference in 1-year survival rate between the two groups (RRN 1.10; 95 CI 0.91-1.33P0.30I224%). The incidence of thrombocytopenia in bronchial artery infusion chemotherapy group was significantly lower than that in systemic intravenous chemotherapy group (RRR 0.64; 95 CI 0.30-1.37; P0. 006; 120%), but there was no significant difference in the incidence of leukopenia between the two groups (RRR0. 77; 95CI0. 56-1. 04; P0. 09; 1287%), and there was no significant difference in the incidence of nausea and vomiting (RR0. 64; 95CIT 0. 30-1.37; P0. 25; I298%). Conclusion: the effective rate of bronchial arterial chemotherapy on advanced non-small cell lung cancer is significantly higher than that of systemic intravenous chemotherapy, and to some extent can reduce the occurrence of some adverse reactions. It can be used as one of the first treatment methods in patients with advanced non-small cell lung cancer (NSCLC).
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R734.2

【相似文献】